N/ARecruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

About this study

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

Enrolling at this location

Mayo Clinic in Arizona

Phoenix, Arizona

I'm interested

This study also enrolls at 2 other locations. See all.

Study details

Conditions

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Colorectal CarcinomaMetastatic Endometrial CarcinomaMetastatic Esophageal CarcinomaMetastatic Liver CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Skin NeoplasmMetastatic Malignant Solid NeoplasmResectable Lung Non-Small Cell CarcinomaEarly Stage Lung Non-Small Cell CarcinomaResectable Malignant Solid NeoplasmResectable Triple-Negative Breast CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Recurrent Cervical CarcinomaRecurrent Colorectal CarcinomaRecurrent Endometrial CarcinomaRecurrent Esophageal CarcinomaRecurrent Liver CarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Malignant Skin NeoplasmRecurrent Malignant Solid Neoplasm

Phase

N/A

Age

18 years and up

Gender

All genders welcome

Healthy volunteers

Not accepted

Last updated

Mar 2026

NCT ID

NCT06349642

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.